Ultra-low-dose continuous combined estradiol and norethisterone acetate: improved bleeding profile in postmenopausal women

References

• IMS Updated Recommendations on postmenopausal hormone therapy. Climacteric 2007; 10: 181–194
   PubMed Web of Science ®Google Scholar
• Estrogen and progestogen use in peri- and postmenopausal women: March 2007 Position Statement of The North American Menopause Society. Menopause 2007; 14: 168–182
   PubMed Web of Science ®Google Scholar
• Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995; 85: 304–313
   PubMed Web of Science ®Google Scholar
• Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1996; 275: 370–375
   PubMed Web of Science ®Google Scholar
• Pike M C, Peters R K, Cozen W, et al. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 1997; 89: 1110–1116
   PubMed Web of Science ®Google Scholar
• Lethaby A, Suckling J, Barlow D, Farquhar C M, Jepson R G, Roberts H. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. Cochrane Database Syst Rev 2004; CD000402
   Google Scholar
• Weiderpass E, Adami H O, Baron J A, et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999; 91: 1131–1137
   PubMed Web of Science ®Google Scholar
• Anderson G L, Judd H L, Kaunitz A M, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA 2003; 290: 1739–1748
   PubMed Web of Science ®Google Scholar
• Beral V, Bull D, Reeves G. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005; 365: 1543–1551
   PubMed Web of Science ®Google Scholar
• Karakoç B, Erenus M. Compliance considerations with hormone replacement therapy. Menopause 1998; 5: 102–106
   PubMed Web of Science ®Google Scholar
• Dören M, Schneider H PG. Long-term compliance of continuous combined oestrogen and progestogen replacement in postmenopausal women. Maturitas 1996; 25: 99–105
   PubMed Web of Science ®Google Scholar
• Thomas A M, Hickey M, Fraser I S. Disturbances of endometrial bleeding with hormone replacement therapy. Hum Reprod 2000; 15(Suppl)7–17
   PubMedGoogle Scholar
• Archer D F, Dorin M, Lewis V, Schneider D L, Pickar J H. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding. Fertil Steril 2001; 75: 1080–1087
   PubMed Web of Science ®Google Scholar
• Mattsson L-Å, Skouby S O, Heikkinen J, Vaheri R, Mäenpää J, Timonen U. A low-dose start in hormone replacement therapy provides a beneficial bleeding profile and few side-effects: randomized comparison with a conventional-dose regimen. Climacteric 2004; 7: 59–69
   PubMed Web of Science ®Google Scholar
• Hammar M, Christau S, Nathorst-Boos J, Rud T, Garre K. A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br J Obstet Gynaecol 1998; 105: 904–911
   PubMedGoogle Scholar
• Staland B. Continuous treatment with natural oestrogens and progestogens. A method to avoid endometrial stimulation. Maturitas 1981; 3: 145–156
   PubMed Web of Science ®Google Scholar
• Mattsson L-Å, Cullberg G, Samsioe G. Evaluation of a continuous combined oestrogen/progestogen regimen for climacteric complaints. Maturitas 1982; 4: 95–102
   PubMed Web of Science ®Google Scholar
• Simon J A, Liu J H, Speroff L, Shumel B S, Symons J P. Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy. Am J Obstet Gynecol 2003; 188: 92–99
   PubMed Web of Science ®Google Scholar
• Simon J A, Symons J P. Unscheduled bleeding during initiation of continuous combined hormone replacement therapy: a direct comparison of two combinations of norethindrone acetate and ethinyl estradiol to medroxyprogesterone acetate and conjugated equine estrogens. Menopause 2001; 8: 321–327
   PubMed Web of Science ®Google Scholar
• Pickar J H, Bottiglioni F, Archer D F. Amenorrhea frequency with continuous combined hormone replacement therapy: a retrospective analysis. Climacteric 1998; 1: 130–136
   PubMedGoogle Scholar
• Johnson J V, Davidson M, Archer D, Bachmann G. Postmenopausal uterine bleeding profiles with two forms of continuous combined hormone replacement therapy. Menopause 2002; 9: 16–22
   PubMed Web of Science ®Google Scholar
• Stadberg E, Mattsson L A, Uvebrant M. 17 beta-estradiol and norethisterone acetate in low doses as continuous combined hormone replacement therapy. Maturitas 1996; 23: 31–39
   PubMed Web of Science ®Google Scholar
• van de Weijer P H, Barentsen R, de Vries M, Kenemans P. Relationship of estradiol levels to breakthrough bleeding during continuous combined hormone replacement therapy. Obstet Gynecol 1999; 93: 551–557
   PubMed Web of Science ®Google Scholar
• Panay N, Ylikorkala O, Archer D, Gut R, Lang E. Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief. Climacteric 2007; 10: 120–131
   PubMed Web of Science ®Google Scholar
• Archer D F, Pickar J H. The assessment of bleeding patterns in postmenopausal women during continuous combined hormone replacement therapy: a review of methodology and recommendations for reporting of the data. Climacteric 2002; 5: 45–59
   PubMed Web of Science ®Google Scholar
• Bakour S H, Dwarakanath L S, Khan K S, Newton J R, Gupta J K. The diagnostic accuracy of ultrasound scan in predicting endometrial hyperplasia and cancer in postmenopausal bleeding. Acta Obstet Gynecol Scand 1999; 78: 447–451
   PubMed Web of Science ®Google Scholar
• Rossouw J E, Anderson G L, Prentice R L, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321–333
   PubMed Web of Science ®Google Scholar
• Banks E, Beral V, Bull D, et al. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419–427
   PubMed Web of Science ®Google Scholar
• Hickey M, Higham J M, Fraser I S. Hormone replacement therapy and irregular bleeding. Climacteric 2001; 4: 95–101
   PubMedGoogle Scholar
• Langer R D, Landgren B M, Rymer J, Helmond F A. Effects of tibolone and continuous combined conjugated equine estrogen/medroxyprogesterone acetate on the endometrium and vaginal bleeding: results of the OPAL study. Am J Obstet Gynecol 2006; 195: 1320–1327
   PubMed Web of Science ®Google Scholar
• von Holst T, Lang E, Winkler U, Keil D. Bleeding patterns in peri and postmenopausal women taking a continuous combined regimen of estradiol with norethisterone acetate or a conventional sequential regimen of conjugated equine estrogens with medrogestone. Maturitas 2002; 43: 265–275
   PubMed Web of Science ®Google Scholar
• Peeyananjarassri K, Baber R. Effects of low-dose hormone therapy on menopausal symptoms, bone mineral density, endometrium, and the cardiovascular system: a review of randomized clinical trials. Climacteric 2005; 8: 13–23
   PubMed Web of Science ®Google Scholar
• Whitehead M I, Townsend P T, Pryse-Davies J, Ryder T A, King R J. Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. N Engl J Med 1981; 305: 1599–1605
   PubMed Web of Science ®Google Scholar
• Persson I, Weiderpass E, Bergkvist L, Bergstrom R, Schairer C. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control 1999; 10: 253–260
   PubMed Web of Science ®Google Scholar
• Wells M, Sturdee D W, Barlow D H, et al. Effect on endometrium of long term treatment with continuous combined oestrogen-progestogen replacement therapy. BMJ 2002; 325: 239–242
   PubMed Web of Science ®Google Scholar
• Kurman R J, Felix J C, Archer D F, Nanavati N, Arce J, Moyer D L. Norethindrone acetate and estradiol-induced endometrial hyperplasia. Obstet Gynecol 2000; 96: 373–379
   PubMed Web of Science ®Google Scholar
• Meuwissen J H, Wiegerinck M A, Haverkorn M J. Regression of endometrial thickness in combination with reduced withdrawal bleeding as a progestational effect of tibolone in postmenopausal women on oestrogen replacement therapy. Maturitas 1995; 21: 121–125
   PubMed Web of Science ®Google Scholar